Scopus BioPharma (Scopus BioPharma) 3-Year FCF Growth Rate : -39.40% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma 3-Year FCF Growth Rate?

Scopus BioPharma's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -39.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Scopus BioPharma was -39.40% per year. The lowest was -136.60% per year. And the median was -88.00% per year.

Competitive Comparison of Scopus BioPharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Scopus BioPharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's 3-Year FCF Growth Rate falls into.

Scopus BioPharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Scopus BioPharma (OTCPK:SCPS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Scopus BioPharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005